Related Experiment Video
Updated: Jun 8, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma
Yusuke Arakawa1, Mitsuo Shimada, Tohru Utsunomiya
1Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Tokushima, Japan.
Objective:
Interferon (IFN) has an anti-tumor activity in hepatocellular carcinoma (HCC) via anti-angiogenesis and induction of apoptosis. We have previously reported anti-metastatic effects of IFN combined chemotherapy on the outcome of HCC patients. The aim of this study was to investigate anti-metastatic effects of IFN.
Methods:
In vitro, pegylated interferon α2b (PEG-IFN-α2b) was administered to mouse MH134 cells (mouse HCC cell line, MH134), and anti-implantation effects were examined by evaluating the inhibition of cell invasion and cell proliferation. Expressions of vascular endothelial growth factor (VEGF) mRNA were also measured. In vivo, PEG-IFN-α2b was subcutaneously administered into MH134 cells and tumor growth was evaluated. In distant metastasis models, PEG-IFN-α2b was subcutaneously administered and MH134 cells were injected into the spleen. The number of liver metastases and microvessel densities (MVD) were counted.
Results:
In vitro, the proliferation of MH134 cells was significantly suppressed by PEG-IFN-α2b dose-dependently. MH134 cells added with PEG-IFN-α2b exhibited significantly lower levels of invasion potential. In vivo, tumor size in mice treated with PEG-IFN-α2b significantly suppressed compared with control mice (mean 0.5 versus 5.0 cm, in diameter, P < 0.05) and also decreased number of liver metastases (19.3 versus 6.0, P < 0.05). Moreover, PEG-IFN-α2b significantly suppressed angiogenesis compared with the control.
Conclusion:
PEG-IFN-α2b in itself had remarkable anti-metastatic effects via inhibition of angiogenesis and cell adhesions.
